Walter & Keenan Financial Consulting Co. MI ADV decreased its stake in Pfizer Inc. (NYSE:PFE) by 2.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 128,113 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the quarter. Pfizer comprises 2.0% of Walter & Keenan Financial Consulting Co. MI ADV’s portfolio, making the stock its 11th biggest holding. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Pfizer were worth $4,648,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in PFE. BlackRock Inc. boosted its holdings in shares of Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock worth $16,308,754,000 after purchasing an additional 6,785,335 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after purchasing an additional 4,998,981 shares during the period. Jensen Investment Management Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth approximately $110,291,000. Neuberger Berman Group LLC boosted its holdings in shares of Pfizer by 17.9% in the 1st quarter. Neuberger Berman Group LLC now owns 16,056,110 shares of the biopharmaceutical company’s stock worth $569,979,000 after purchasing an additional 2,432,694 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in shares of Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock worth $1,431,069,000 after purchasing an additional 1,671,311 shares during the period. Hedge funds and other institutional investors own 68.96% of the company’s stock.
Shares of NYSE PFE opened at $44.28 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market cap of $264.31 billion, a price-to-earnings ratio of 14.90, a PEG ratio of 2.24 and a beta of 0.88. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.81.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. Pfizer’s revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. Research analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.
A number of equities research analysts recently issued reports on PFE shares. BMO Capital Markets raised their price target on Pfizer from $42.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 1st. Jefferies Financial Group set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, July 31st. Barclays set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 29th. Morningstar set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Finally, Deutsche Bank set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 21st. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $42.67.
In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the sale, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Pfizer Inc bought 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the transaction, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The disclosure for this purchase can be found here. Insiders own 0.06% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.